2006, Number S2
ST elevation acute coronary syndromes. Pharmaco-mechanic strategy is the universal treatment future?
PDF size: 92.65 Kb.
ABSTRACTThe main objective in the medical treatment of the ST elevation acute myocardial infarction, must have the intention to reperfuse the culprit involved artery. In order to reduce this time, the pharmaco-invasive strategy may offer rapid flow recanalization in the culprit artery and reduce the damage of the myocardium. The new pharmacologic combinations includes half dose of fibrinolytics, alone or in combination with IIb/IIIa inhibitors, this combination may offer advantages of the flow. This concept involves the that PCI (Percutaneous Coronary Interventions), can be done in a subsequent time. The risk of bleeding is increased with this strategy, and some evaluation or bleeding risk must be done in all patients, as in patients with 75 years and older.
REMIER KA, LOWE JE, RASMUSSEN M, JENINNGS R: The wave front phenomenon of ischemic cell death. 1 Myocardial size vs duration of coronary occlusion in dogs. Circulation 1977; 56: 786-794.
OHMAN EM, CALIFF RM, TOPOL EJ, CANDELA R, ABBOTTSMITH C, ELLIS S, SIGMON KN, KEREIAKES D, GEORGE B, STACK R: Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. TAMI Study Group: Circulation 1990; 82: 781-791.
GIBBSON M, CANNON C, PIANA R, ET AL: Angiographic predictors of reocclusion after thrombolysis: Results from the thrombolysis in myocardial infarction (TIMI) 4 Trial. JACC 1995; 25: 582-589.
STEG G, BONNEFOY E, CHABAUD S, ET AL: Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty. Data from the CAPTIM randomized clinical trial. Circulation 2003; 108: 2851-2856.
DE LUCA G, SURYAPRANATA H, ZIJLSTRA F: Symptom onset to balloon time and mortality in patients with acute myocardial infarction treated with primary angioplasty. JACC 2003; 42: 991-997.
BONNEFOY E, LAPOSTOLLE F, LEIZOROVICZ A, ET AL: Primary PTCA vs Pre-hospital fibrinolysis in acute myocardial infarction: a randomized study. Lancet 2002; 360: 825-829.
DANCHIN N, BLANCHARD D, STEG PG, SAUVAL P, HANANIA G, GOLDSTEIN P, CAMBOU JP, GUERET P, VAUR L, BOUTALBI Y, GENES N, LABLANCHE JM, USIC 2000 Investigators. Impact of prehospital thrombolysis for acute myocardial infarction on 1-year outcome: results from the French Nationwide USIC 2000 Registry: Circulation 2004; 110: 1909-1915.
WIDIMSKY P, GROCH L, ZELÍZKO M, ET AL: Multicentre randomized trial comparing transport to primary angioplasty vs immediate thrombolysis vs combined strategy for patients with acute myocardial infarction presenting to a community hospital without a catheterization laboratory. The Prague study. Eur Heart Journal 2000; 21: 823-31.
DAUERMAN H, SOBEL B, ET AL: Synergistic treatment of ST elevation myocardial infarction with pharmacoinvasive recanalization. JACC ; 42: 646-51.
MARTÍNEZ M, ROSAS M, GONZÁLEZ H, ET AL: Comparison of reperfusion regimens with or without tirofiban in ST elevation acute myocardial infarction. SASTRE. Am J Cardiol 2004; 93: 280-287.
ASSENT-4-PCI: Full dose of TNK plus primary PTCA vs primary PTCA in acute myocardial infarction. (presentación oral en el Congreso Europeo de Cardiología. Estocolmo Suecia Agosto del 2005).
ANTMAN E, VAN DER WERF: Pharmaco-invasive therapy. The future of treatment for ST elevation myocardial infarction. Circulation 2004; 109: 2480-86.